GO:0097045 phosphatidylserine exposure on blood platelet: Procoagulant Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0097045 describes the phospholipid scrambling process that exposes phosphatidylserine (PS) on the outer surface of activated blood platelets, triggering the clotting system.
• PS exposure is a hallmark of platelet activation and is mechanistically linked to calcium-dependent scramblase activity and loss of aminophospholipid translocase function.
• Platelet PS exposure is essential for assembly of the tenase and prothrombinase complexes, accelerating thrombin generation by orders of magnitude.
• Platelet senescence and storage also drive PS exposure, contributing to the procoagulant phenotype of aged or stored platelets.
• Pharmacological inhibitors such as ethyl pyruvate and tetramethylpyrazine reduce platelet PS exposure, highlighting therapeutic targets.
• Measuring PS exposure and microvesicle release from purified platelets is a standardized approach for characterizing procoagulant platelets.
Description
Phosphatidylserine (PS) is an aminophospholipid normally confined to the inner leaflet of the platelet plasma membrane. Upon strong activation, platelets undergo a dramatic reorganization of their membrane phospholipids, exposing PS on the outer surface. This process, formally annotated as GO:0097045 (phosphatidylserine exposure on blood platelet), is a phospholipid scrambling event that converts the platelet surface into a catalytic platform for blood coagulation. The exposed PS serves as a binding site for gamma-carboxyglutamic acid (Gla)-domain-containing coagulation factors, thereby accelerating the tenase and prothrombinase reactions and thrombin generation. Researchers study GO:0097045 because it sits at the intersection of platelet biology, hemostasis, and thrombosis. Dysregulated PS exposure contributes to pathological thrombosis, while impaired PS exposure can cause bleeding disorders. The process is also relevant to platelet storage lesions, where PS exposure on stored platelets promotes microvesicle release and transfusion-related complications. Recent work has identified mitochondrial regulators such as Mitofusin-2 (MFN2) that modulate platelet mitochondria and function, indirectly influencing PS exposure. This article provides a research-grade overview of GO:0097045, covering its definition, molecular players, regulatory mechanisms, disease links, and experimental models. It is intended for scientists designing CRISPR screens, knockout models, or pharmacological studies targeting platelet procoagulant activity.
phosphatidylserine exposure on blood platelet At A Glance
| GO ID | GO:0097045 |
|---|---|
| GO term | phosphatidylserine exposure on blood platelet |
| Ontology | biological_process |
| Synonym | none |
| Major function | Phospholipid scrambling that externalizes phosphatidylserine on activated platelets, triggering the clotting system |
| Cellular location | Blood platelet plasma membrane |
| Trigger | Platelet activation (e.g., by thrombin, collagen, calcium ionophores) |
| Key molecular players | TMEM16F (ANO6) scramblase, TMEM16F-dependent calcium signaling, aminophospholipid translocase (flippase) inactivation |
| Physiological consequence | Assembly of tenase and prothrombinase complexes, thrombin generation, fibrin formation |
What Is GO:0097045?
GO:0097045, phosphatidylserine exposure on blood platelet, is a biological process defined as a phospholipid scrambling process that results in the appearance of phosphatidylserine on the surface of activated blood platelets, and triggers the clotting system. In simpler terms, it is the flipping of PS from the inner to the outer leaflet of the platelet membrane upon activation, which makes the platelet surface procoagulant.
Why Is phosphatidylserine exposure on blood platelet Important in Cell Biology?
GO:0097045 is critically important because PS exposure on platelets is the central event that converts a resting platelet membrane into a procoagulant surface. Without PS externalization, the coagulation cascade cannot efficiently assemble the tenase and prothrombinase complexes, leading to defective thrombin generation and bleeding. Conversely, excessive or premature PS exposure contributes to thrombosis, stroke, and other cardiovascular pathologies. The process is also a key mechanism in platelet storage lesion, where PS-positive platelets and microvesicles accumulate during blood bank storage, potentially causing transfusion reactions. Understanding GO:0097045 therefore has direct implications for anticoagulant therapy, antiplatelet drug development, and transfusion medicine.
• PS exposure is required for efficient thrombin generation and fibrin clot formation.
• It is a hallmark of procoagulant platelets, a distinct subpopulation with high coagulant activity.
• Platelet senescence and storage induce PS exposure, contributing to transfusion-related complications.
• Inhibitors such as ethyl pyruvate reduce PS exposure, suggesting anti-inflammatory and antithrombotic strategies.
• Pathological high shear rates promote platelet PS exposure, relevant to stenosis and thrombosis.
• Aquaporins modulate platelet function and may influence PS exposure indirectly.
• Mitochondrial dynamics regulated by MFN2 affect platelet function and survival, with potential impact on PS exposure.
• PS exposure is a marker of platelet activation in flow cytometry and microfluidic assays.
• Defects in PS exposure can cause Scott syndrome, a rare bleeding disorder.
• Targeting PS exposure may reduce thrombotic risk without causing excessive bleeding.
What Happens During phosphatidylserine exposure on blood platelet?
Platelet Activation and Calcium Influx
In simple terms: When platelets are activated, calcium rushes into the cell, which is the trigger for flipping PS to the outside.
Platelet activation by agonists such as thrombin, collagen, or calcium ionophores leads to a sustained increase in cytosolic calcium concentration. This calcium signal is required for the activation of scramblase enzymes and the inactivation of aminophospholipid translocases (flippases) that normally keep PS in the inner leaflet. The rise in intracellular calcium is a prerequisite for PS exposure, as calcium chelation prevents the process.
Phospholipid Scrambling and Loss of Membrane Asymmetry
In simple terms: The membrane loses its normal asymmetry, and PS moves from the inside to the outside.
Under resting conditions, the platelet plasma membrane is asymmetric, with PS and phosphatidylethanolamine concentrated in the inner leaflet. Upon activation, calcium-dependent scramblases, notably TMEM16F (ANO6), are activated and catalyze bidirectional phospholipid movement across the bilayer. Simultaneously, flippase activity is inhibited, allowing PS to accumulate on the outer surface. This scrambling process is rapid and can be measured by annexin V binding.
Assembly of Coagulation Factor Complexes
In simple terms: Exposed PS acts like a docking station for clotting factors, speeding up blood clotting.
Once PS is exposed, it serves as a high-affinity binding site for Gla-domain-containing coagulation factors, including factors VIIa, IXa, Xa, and prothrombin. This assembly facilitates the formation of the tenase (FVIIIa-FIXa) and prothrombinase (FVa-FXa) complexes, which dramatically accelerate the activation of factor X and prothrombin, respectively. The result is a burst of thrombin generation and subsequent fibrin polymerization.
Microvesicle Release and Procoagulant Platelet Formation
In simple terms: Some activated platelets shed small bubbles that also carry PS and promote clotting.
Strongly activated platelets can release PS-positive microvesicles (also called microparticles) from their membrane. These microvesicles retain procoagulant activity and amplify thrombin generation. The formation of procoagulant platelets, a subpopulation with sustained PS exposure, is a key feature of thrombus formation under flow. Mitochondrial function and dynamics, regulated by proteins such as MFN2, may influence the viability and procoagulant capacity of platelets.
Regulation by Pharmacological and Physiological Modulators
In simple terms: Certain drugs and natural compounds can turn down PS exposure, reducing clotting risk.
Ethyl pyruvate, a stable pyruvate derivative, inhibits platelet aggregation and PS exposure in vitro. Tetramethylpyrazine, a compound used in traditional Chinese medicine, reduces platelet aggregation, activation, and PS exposure under pathological high shear rates. Aquaporins, water channel proteins, are expressed in platelets and may modulate volume changes associated with activation, indirectly affecting PS exposure. These findings suggest multiple points of regulation for GO:0097045.
Key Genes Involved in GO:0097045 phosphatidylserine exposure on blood platelet
The following genes and proteins are experimentally implicated in platelet phosphatidylserine exposure, either as direct mediators or as modulators of platelet activation and procoagulant function.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ANO6 (TMEM16F) | Calcium-activated phospholipid scramblase | Direct mediator of PS exposure; mutations cause Scott syndrome |
| MFN2 | Mitochondrial fusion protein | Regulates platelet mitochondria and function; may influence PS exposure |
| AQP1 | Aquaporin water channel | Modulates platelet volume and activation; potential indirect role |
| AQP4 | Aquaporin water channel | Expressed in platelets; may affect activation responses |
| F2 (Prothrombin) | Coagulation factor | Thrombin generation downstream of PS exposure |
| F10 (Factor X) | Coagulation factor | Assembles on PS surface for prothrombinase complex |
| F5 (Factor V) | Coagulation factor | Cofactor in prothrombinase complex on PS |
| F8 (Factor VIII) | Coagulation factor | Cofactor in tenase complex on PS |
| F9 (Factor IX) | Coagulation factor | Serine protease in tenase complex |
| SLC44A1 | Choline transporter-like protein | May regulate phospholipid metabolism in platelets |
| PLSCR1 | Phospholipid scramblase 1 | Potential contributor to PS exposure in some cell types |
| XKR8 | XK-related protein 8 | Scramblase involved in apoptotic PS exposure; not confirmed in platelets |
| P2RX1 | Purinergic receptor | Mediates calcium influx in platelets, upstream of PS exposure |
| STIM1 | Calcium sensor | Regulates store-operated calcium entry in platelets |
| ORAI1 | Calcium channel | Store-operated calcium entry; affects platelet activation |
| ITPR1 | IP3 receptor | Mediates calcium release from intracellular stores |
| CALR | Calreticulin | Calcium-binding chaperone; may affect calcium signaling |
How Is phosphatidylserine exposure on blood platelet Regulated?
The regulation of phosphatidylserine exposure on blood platelets is primarily driven by intracellular calcium signaling. Agonist-induced calcium influx and release from intracellular stores activate scramblases and inhibit flippases, tipping the balance toward PS externalization. Mitochondrial function, governed by proteins such as Mitofusin-2 (MFN2), can influence platelet viability and procoagulant activity, as MFN2 deficiency alters platelet mitochondria and function. Aquaporins may modulate platelet volume and activation, potentially affecting PS exposure indirectly. Pharmacological agents such as ethyl pyruvate and tetramethylpyrazine can suppress PS exposure, indicating that redox and shear-sensitive pathways are involved. Additionally, platelet senescence and storage conditions promote PS exposure, likely through cumulative oxidative stress and calcium dysregulation.
phosphatidylserine exposure on blood platelet and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ANO6 (TMEM16F) | Scott syndrome; defective PS exposure | Knockout megakaryocyte cell line; patient-derived iPSC-derived platelets |
| MFN2 | Platelet mitochondrial dysfunction; thrombosis | Platelet-specific Mfn2 knockout mouse |
| F2 | Thrombophilia; bleeding | Point mutation knock-in in hepatocyte-like cells |
| F5 | Factor V Leiden thrombophilia | Knock-in of F5 Leiden mutation in cell models |
| P2RX1 | Platelet activation disorders | Knockout in megakaryocytic cell lines |
Thrombosis and Cardiovascular Disease
Excessive platelet PS exposure contributes to pathological thrombus formation. Procoagulant platelets with exposed PS are found in arterial thrombi and are associated with myocardial infarction and stroke. Under pathological high shear rates, such as in stenotic arteries, platelet aggregation and PS exposure are enhanced, promoting occlusive thrombosis. Targeting PS exposure may therefore reduce thrombotic risk.
Scott Syndrome (Bleeding Disorder)
Scott syndrome is a rare inherited bleeding disorder characterized by defective platelet PS exposure and impaired thrombin generation. Mutations in ANO6 (TMEM16F) are a known cause of Scott syndrome, highlighting the essential role of this scramblase in GO:0097045. Patients present with mild to moderate bleeding despite normal platelet counts and coagulation factor levels.
Platelet Storage Lesion and Transfusion Medicine
During blood bank storage, platelets undergo progressive activation and senescence, leading to PS exposure and microvesicle release. These changes reduce post-transfusion platelet recovery and may cause transfusion reactions. Measuring PS exposure is a quality control parameter for stored platelet concentrates.
Inflammation and Sepsis
Sepsis and systemic inflammation can trigger platelet activation and PS exposure, contributing to disseminated intravascular coagulation (DIC). Ethyl pyruvate, an anti-inflammatory agent, inhibits platelet aggregation and PS exposure, suggesting a link between inflammation and procoagulant platelet phenotype.
From phosphatidylserine exposure on blood platelet-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate PS exposure? | CRISPR knockout in HEL or MEG-01 megakaryocytic cell lines, followed by annexin V flow cytometry |
| Does a point mutation in ANO6 affect scramblase activity? | CRISPR point mutation knock-in in HEK293T or megakaryocytic cells |
| Can a candidate gene rescue PS exposure? | Overexpression of wild-type or mutant gene in knockout background |
| What is the role of mitochondrial dynamics in PS exposure? | Platelet-specific Mfn2 knockout mouse |
| How does shear stress affect PS exposure? | Microfluidic chip with pathological high shear rate |
| Does a drug inhibit PS exposure? | Human purified platelets treated with compounds, measured by annexin V binding |
How to Study the phosphatidylserine exposure on blood platelet Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Annexin V flow cytometry | PS exposure on platelet surface | Quantify procoagulant platelets after activation |
| Microfluidic assay | Platelet aggregation and PS exposure under shear | Study thrombosis under pathological flow |
| CRISPR knockout screen | Genes required for PS exposure | Identify novel regulators in megakaryocytic cells |
| CRISPR point mutation | Effect of specific mutations on scramblase function | Model Scott syndrome or other bleeding disorders |
| Overexpression | Gain-of-function of candidate genes | Test if gene X enhances PS exposure |
| Proteomics | Protein expression and phosphorylation changes | Map signaling pathways upstream of PS exposure |
| Confocal microscopy | PS localization and scramblase trafficking | Visualize membrane dynamics during activation |
| Thrombin generation assay | Functional consequence of PS exposure | Measure procoagulant activity of platelets |
Flow Cytometry with Annexin V
Annexin V binds to exposed PS with high affinity and is the gold standard for measuring PS exposure on platelets. Flow cytometry allows quantification of PS-positive platelets and microvesicles. This method is widely used to assess platelet activation and procoagulant phenotype.
Microfluidic Assays
Microfluidic chips can simulate physiological and pathological shear rates to study platelet aggregation, activation, and PS exposure under flow. This approach has been used to demonstrate the inhibitory effect of tetramethylpyrazine on PS exposure mediated by high shear rate.
CRISPR Screening and Gene Editing
CRISPR knockout screens in megakaryocytic cell lines can identify genes required for PS exposure. Point mutations can be introduced to model Scott syndrome or other coagulation disorders. Knock-in of tagged scramblases allows live-cell imaging of protein localization during activation.
Proteomics and Phosphoproteomics
Mass spectrometry-based proteomics can quantify changes in platelet membrane proteins and phosphorylation events during PS exposure. This helps identify signaling pathways upstream of scramblase activation.
How CRISPR Can Be Used to Study GO:0097045 phosphatidylserine exposure on blood platelet
Knockout
CRISPR knockout of candidate genes such as ANO6, MFN2, or P2RX1 in megakaryocytic cell lines (e.g., HEL, MEG-01) or primary megakaryocytes can determine whether the gene is required for PS exposure. Knockout of ANO6 is expected to abolish calcium-induced PS exposure, mimicking Scott syndrome. Platelet-specific knockout mice can be generated for in vivo studies.
Point Mutation
Point mutations in ANO6 or other genes can be introduced using CRISPR base editing or homology-directed repair to model disease-associated variants. For example, mutations causing Scott syndrome can be knocked into cell lines to study their effect on scramblase activity and PS exposure.
Knock-in
Knock-in of fluorescent tags (e.g., GFP) or epitope tags into endogenous genes allows real-time tracking of protein localization during platelet activation. Tagged ANO6 knock-in cells can be used to visualize scramblase trafficking to the plasma membrane upon calcium elevation.
Overexpression
Overexpression of wild-type or mutant forms of scramblases or regulatory proteins can test gain-of-function effects on PS exposure. For example, overexpressing constitutively active ANO6 may increase basal PS exposure, while overexpressing flippases may reduce it. This approach is useful for validating candidate genes from screens.
How EDITGENE Supports phosphatidylserine exposure on blood platelet Research
Researchers studying phosphatidylserine exposure on blood platelet-related genes often need to determine whether a candidate gene is causally involved in PS externalization, microvesicle release, or procoagulant activity. EDITGENE provides a comprehensive suite of CRISPR services to accelerate this research, from knockout to knock-in and library screening.
Contact EDITGENE today to design your custom CRISPR model for phosphatidylserine exposure on blood platelet research.
Frequently Asked Questions About phosphatidylserine exposure on blood platelet
What is phosphatidylserine exposure on blood platelet (GO:0097045)?
It is the process by which activated platelets flip phosphatidylserine from the inner to the outer leaflet of their membrane, triggering blood clotting.
What genes are involved in phosphatidylserine exposure on blood platelets?
Key genes include ANO6 (TMEM16F), MFN2, P2RX1, and coagulation factors such as F2, F5, F8, F9, and F10.
How is phosphatidylserine exposure measured?
Annexin V binding followed by flow cytometry is the standard method to quantify PS exposure on platelets.
What diseases are associated with defective phosphatidylserine exposure?
Scott syndrome is a bleeding disorder caused by defective PS exposure, often due to ANO6 mutations.
Can phosphatidylserine exposure be inhibited pharmacologically?
Yes, compounds such as ethyl pyruvate and tetramethylpyrazine have been shown to inhibit platelet PS exposure.
What is the role of calcium in phosphatidylserine exposure?
Calcium influx activates scramblases and inhibits flippases, leading to PS externalization.
How does platelet storage affect phosphatidylserine exposure?
Platelet storage induces senescence and PS exposure, which can reduce post-transfusion recovery.
What is the link between phosphatidylserine exposure and thrombosis?
Excessive PS exposure promotes thrombin generation and thrombus formation, especially under high shear stress.
Which cell models are used to study phosphatidylserine exposure?
Megakaryocytic cell lines like HEL and MEG-01, as well as primary platelets and platelet-specific knockout mice, are commonly used.
How can CRISPR help study phosphatidylserine exposure?
CRISPR knockout, knock-in, and point mutation models allow functional dissection of genes regulating PS exposure in platelet-like cells.
Conclusion
GO:0097045, phosphatidylserine exposure on blood platelet, is a fundamental biological process that links platelet activation to coagulation. Its dysregulation contributes to both bleeding and thrombotic disorders, making it a compelling target for research and therapeutic intervention. Advances in CRISPR gene editing and microfluidic technologies are accelerating the discovery of molecular players and modulators of this process. EDITGENE provides the tools and expertise to dissect the genetic basis of PS exposure and translate findings into clinical applications.
References
- 1. Jacob S et al.. 2024. Mitofusin-2 Regulates Platelet Mitochondria and Function.. Circ Res 134(2):143-161 PMID: 38156445
- 2. Lentz BR. 2003. Exposure of platelet membrane phosphatidylserine regulates blood coagulation.. Prog Lipid Res 42(5):423-38 PMID: 12814644
- 3. Nagata S et al.. 2016. Exposure of phosphatidylserine on the cell surface.. Cell Death Differ 23(6):952-61 PMID: 26891692
- 4. Dasgupta SK et al.. 2010. Platelet senescence and phosphatidylserine exposure.. Transfusion 50(10):2167-75 PMID: 20456701
- 5. Li W et al.. 2017. Inhibitory effects of ethyl pyruvate on platelet aggregation and phosphatidylserine exposure.. Biochem Biophys Res Commun 487(3):560-566 PMID: 28427942
- 6. Zhang T et al.. 2023. Application of microfluidic chip technology to study the inhibitory effect of tetramethylpyrazine on platelet aggregation, activation, and phosphatidylserine exposure mediated by pathological high shear rate.. Blood Coagul Fibrinolysis 34(1):47-60 PMID: 36367784
- 7. Fiore M et al.. 2024. Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets.. J Vis Exp PMID: 39671342
- 8. Agbani EO et al.. 2021. Aquaporins in platelet function.. Platelets 32(7):895-901 PMID: 33818240
